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An extensive protein–protein interaction network has been identiﬁed between proteins implicated in inher-
ited ataxias. The protein sacsin, which is mutated in the early-onset neurodegenerative disease autosomal
recessive spastic ataxia of Charlevoix-Saguenay, is a node in this interactome. Here, we have established
the neuronal expression of sacsin and functionally characterized domains of the 4579 amino acid protein.
Sacsin is most highly expressed in large neurons, particularly within brain motor systems, including cereb-
ellar Purkinje cells. Its subcellular localization in SH-SY5Y neuroblastoma cells was predominantly
cytoplasmic with a mitochondrial component. We identiﬁed a putative ubiquitin-like (UbL) domain at the
N-terminus of sacsin and demonstrated an interaction with the proteasome. Furthermore, sacsin contains
a predicted J-domain, the deﬁning feature of DnaJ/Hsp40 proteins. Using a bacterial complementation
assay, the sacsin J-domain was demonstrated to be functional. The presence of both UbL and J-domains
in sacsin suggests that it may integrate the ubiquitin–proteasome system and Hsp70 function to a speciﬁc
cellular role. The Hsp70 chaperone machinery is an important component of the cellular response towards
aggregation prone mutant proteins that are associated with neurodegenerative diseases. We therefore inves-
tigated the effects of siRNA-mediated sacsin knockdown on polyglutamine-expanded ataxin-1. Importantly,
SACS siRNA did not affect cell viability with GFP-ataxin-1[30Q], but enhanced the toxicity of GFP-ataxin-
1[82Q], suggesting that sacsin is protective against mutant ataxin-1. Thus, sacsin is an ataxia protein
and a regulator of the Hsp70 chaperone machinery that is implicated in the processing of other ataxia-
linked proteins.
INTRODUCTION
Causative genes have been identiﬁed for at least 45 inherited
ataxias. These neurodegenerative disorders include autosomal
dominant ataxias, such as the polyglutamine-mediated
spinocerebellar ataxias, and the recessive diseases Friedreich’s
ataxia and autosomal recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS) (1).
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common interacting partners indicating that they are
functionally linked (2). Furthermore, although the clinical fea-
tures of these conditions are variable there is substantial evi-
dence for overlapping pathways of molecular pathogenesis
in some forms of ataxia. These include perturbations in
normal protein homeostasis that invoke cellular responses
from both molecular chaperone and ubiquitin–proteasome
systems (UPS).
Hsp70 molecular chaperone networks are associated with
neurodegenerative diseases where protein conformational
changes and subsequent aberrant protein folding are a
feature (3). The pathogenesis of these conditions usually
includes the formation of deposits of misfolded ubiquitylated
protein with which Hsp70 and Hsp40/DnaJ proteins are fre-
quently associated. Hsp70 and its co-chaperones, particularly
Hsp40 proteins, have also been recognized as potent modu-
lators of protein aggregation and survival in cellular and
animal models of neurodegenerative disease (3).
The Hsp70 molecular chaperone machine also functions in
targeting proteins to the UPS for degradation. For example,
the co-chaperone CHIP (C-terminus of Hsc70-interacting
protein), which regulates Hsp70 chaperone activity and acts
as an ubiquitin ligase for Hsp70 clients (4), has been shown
to interact with ataxia proteins such as ataxin-1, thereby mod-
ulating their solubility and degradation.
ARSACS (OMIM: 270550) is characterized by early-onset
spastic ataxia. Pathological features include atrophy of the
upper cerebellar vermis and absence of Purkinje cells (5).
Mutations in the SACS gene were identiﬁed as causing
ARSACS in a Canadian population (6). Subsequent genetic
studies indicate that this form of spastic ataxia may be far
more common than originally presumed and have a global dis-
tribution (7). Initially, the SACS gene was reported to consist
of one 12 794 bp exon (6), in which homozygous missense,
nonsense and frameshift mutations have been found. Recently,
further mutations have been reported in newly identiﬁed 50
exons (7,8).
The SACS gene is predicted to encode a large multidomain
protein, sacsin, which has regions of sequence similarity to
several proteins. The strongest similarity identiﬁed was
between a region near the C-terminus of sacsin and the
J-domain of Hsp40 proteins (approximately 60% identity
over 30 residues compared with Hsp40/Hdj1). The highly con-
served J-domain is the deﬁning feature of the Hsp40 family of
Hsp70 co-chaperones (9). Therefore, sacsin may represent a
direct link between ataxia and the Hsp70 machinery.
This study represents the ﬁrst characterization of sacsin. We
have deﬁned the localization of the sacsin protein in brain. The
data show that sacsin has nine coding exons. We identiﬁed a
ubiquitin-like (UbL) domain at the N-terminus of sacsin that
can interact with the proteasome. Furthermore, we used an
in vivo assay to demonstrate that the J-domain of sacsin is
functional. Finally, sacsin knockdown resulted in a reduction
in cells expressing polyglutamine-expanded ataxin-1, which
correlated with a loss of cells with large nuclear ataxin-1
inclusions. Together these data suggest that the large multi-
domain sacsin protein is able to recruit Hsp70 chaperone
action and has the potential to regulate the effects of other
ataxia proteins.
RESULTS
Sacsin is expressed in the cell bodies and processes
of neurons
The human SACS gene was initially reported to contain a
single massive exon encoding a 11.5 kb open reading frame
(6). Subsequently eight additional 50 putative coding exons
have been annotated. We conﬁrmed that the human gene tran-
scribed a 9 exon transcript, which is predicted to code a 4579
amino acid protein (NM_014363.4), by reverse transcriptase-
polymerase chain reaction (RT–PCR) analysis of human
brain mRNA (Supplementary Material, Fig. S1). In mouse, a
sacsin isoform of 4579 amino acids, with a molecular
weight of 520 kDa, is also predicted (UniProt accession
number: Q9JC8).
To analyse the expression and localization of sacsin we
developed an antiserum (r-sacsin
1–17) to the N-terminus of
sacsin and an antiserum (r-sacsin
4489–4503) to a peptide
sequence, which is located near the C-terminus. Western
analysis of mouse and rat tissues with r-sacsin
4489–4503
detected a speciﬁc band of approximately 520 kDa in brain
which was competed with immunizing peptide (Fig. 1A and
B). r-Sacsin
1–17 was unsuitable for western blotting (not
shown).
We performed immunohistochemistry and in situ hybridiz-
ation on rat brain sections using r-sacsin
4489–4503 and SACS
probes. In Supplementary Material, Figure S2, ﬁlm autoradio-
grams of in situ hybridization signal are presented to show the
overall distribution of expression. There was a strong corre-
lation between the localization of immunoreactivity and
SACS mRNA at the cellular level (Fig. 1). Expression
appeared predominantly, if not exclusively neuronal, with
sacsin protein localized to the cytoplasm of neuronal cell
bodies and processes including both dendrites and axons, the
latter as evidenced by axonal tract labelling. Examination of
sections with dual-label immunoﬂuorescence histochemistry
for r-sacsin
4489–4503 and NeuN, a neuron-speciﬁc marker
that labels most neuronal cell populations (10), conﬁrmed
that all NeuN-positive neurons expressed detectable levels of
sacsin protein (data not shown), therefore, there were no
clear examples of sacsin-negative neurons.
In the forebrain, cerebral cortex expression of SACS mRNA
and sacsin protein was abundant with large layer 5 corticosp-
inal neurons expressing the highest levels (Fig. 1C and D).
Neuropil labelling for sacsin immunoreactivity was prominent
in the striatum and ﬁbre tracts, such as the anterior commis-
sure, exhibited ﬁne labelling (Fig. 1E). In the thalamus
expression levels for both mRNA and protein varied
between nuclei with the anterodorsal nucleus showing
highest expression (Fig. 1F–H).
In the cerebellum, Purkinje cells had the highest levels of
expression of both SACS mRNA and sacsin protein. The mol-
ecular layer with Purkinje cell dendrites and contacting affer-
ents was clearly stained for sacsin protein (Fig. 1I–K).
Between the forebrain and brainstem, an almost continuous
band of large neurons expressing high levels of SACS mRNA
and sacsin protein extended from the basal forebrain magno-
cellular system through the zona incerta and pontine and
medullary reticular formation (Fig. 1L and M). Neurons of
precerebellar nuclei including the red, pontine, vestibular
Human Molecular Genetics, 2009, Vol. 18, No. 9 1557Figure 1. Sacsinispredominantlyexpressed in thecellbodiesand processesof neurons.Western analysis of mouseandrat tissueswas performed usingan afﬁnity-
puriﬁed polyclonal antiserum (r-sacsin
4489–4503). (A) r-Sacsin
4489–4503 detected a band of .500 kDa in neuronal tissues. The band was not detected when
r-sacsin
4489–4503 was pre-incubated withimmunizing peptide. (B) Sacsin was detected in braintissue and in testis.(C–Q) In situ hybridization withemulsion auto-
radiography for SACS mRNA and immunohistochemistry for sacsin protein was performed in rat brain. Sacsin was detected with r-sacsin
4489–4503 in D–E, H, J, K,
M–O, and with r-sacsin
1–17in P and Q. Layer 5 of the cerebral cortex labelled for SACS mRNA (C) and protein immunoreactivity (D). Larger pyramidal neurons
(arrows) had higher expression of both SACS mRNA and sacsin protein than smaller neuronal proﬁles (arrowhead). (E) Immunohistochemistry showing axonal
labellingintheanteriorcommissure(ac)andheavyneuropillabellinginthenucleusaccumbens(Acb).(F)SACSmRNAsignalwashigherintheanterodorsalthala-
mus (AD) than the mediodorsal thalamus (MD). The stria medullaris (sm) had no detectable SACS mRNA. (G) Competition control resulted in the loss of speciﬁc
signal. (H) Immunohistochemistry of the same region showed an identical labelling pattern. (I) Cerebellum in situ hybridization showed high levels of signal over
Purkinje cells (Pk), with cells of the granule cell layer (Gc) expressing moderate levels. (J) Immunoreactivity for sacsin was high in Purkinje cells and lower in
granulecells.Themolecularlayer(Mo)haddenseimmunoreactivity.(L)Themagnocellularpreopticnucleusneuronshadrelativelyhighlevelsofautoradiographic
signal (arrows) with smaller neurons considerably less labelled (arrowhead). (M) Large neurons (arrow) of the gigantocellular reticular nucleus had high levels of
immunoreactivity. Primary dendrites and surrounding ﬁbrous neuropil also labelled. (N) In the medial vestibular nucleus, both large and small neurons and the sur-
rounding ﬁbrous neuropil prominently stained. (O) Large motorneurons in the motor trigeminal nucleus (large arrow) had intense immunoreactivity. Fine, labelled
axons(smallarrows) in theadjacentmotorrootof the trigeminalnervewere observed.(P) In layer5 of the cortex, the N-terminalsacsinantibody stained pyramidal
neuronsintenselyasdidtheC-terminalantibody(D)butlabelleddendriticprocessesaswell.(KandQ)InpeptideabsorptioncontrolsofanalogoussectionsinJand
P, respectively, immunoreactivity was signiﬁcantly reduced. Scale bar ¼ 40 mm in (C and D) and (I–Q); 90 mm in (E–H).
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relatively high levels of expression (Fig. 1M–O). Brainstem
sensory nuclei including the nucleus of the trapezoid body,
cochlear nuclei and sensory trigeminal nerve nuclei had mod-
erate expression. Large neurons of the mesencephalic nucleus
of the trigeminal nerve expressed very high levels of the
mRNA (Supplementary Material, Fig. S2).
The N-terminal antiserum r-sacsin
1–17 in immunohisto-
chemistry produced a very similar staining pattern to that
observed with r-sacsin
4489–4503, although the staining of den-
dritic processes was more intense using r-sacsin
1–17as shown
in layer 5 cerebral cortex (Fig. 1P).
Controls for speciﬁcity of in situ hybridization (Fig. 1G) and
immunohistochemistry (Fig. 1K and Q), using excess oligonu-
cleotide or immunizing peptides respectively, eliminated or
dramatically reduced labelling.
Sacsin has a predominantly cytoplasmic distribution with a
mitochondrial component
SACSisexpressedinthehumanneuroblastomaderivedcellline
SH-SY5Y(SupplementaryMaterial,Fig.S5).Weexaminedthe
subcellularlocalizationofendogenoussacsininSH-SY5Ycells
bystainingwithr-sacsin
1–17andr-sacsin
4489–4503.BothN-and
C-terminalsacsinantibodiesproducedthesamestainingpattern
(Fig. 2A–D). The protein had a predominantly cytoplasmic
localization with some punctate staining also visible. A small
proportion of sacsin immunoreactivity appeared nuclear (Sup-
plementary Material, Fig. S3). Interestingly, bioinformatics
analysis revealed that sacsin contains multiple putative
nuclear localization signals (Supplementary Material,
Table S1). To further investigate the subcellular distribution
of sacsin we tested for co-localization between sacsin and
speciﬁc organelle markers. Sacsin immunoreactivity partially
overlapped with the distribution of MitoTracker (Fig. 2E–G)
a mitochondrial ﬂuorescent probe, and the mitochondrial
protein Hsp60 (Supplementary Material, Fig. S3). The
overlapbetweensacsinlocalizationandMitoTrackerwasquan-
tiﬁed using MetaMorph 7.5 image analysis software. About
30%+3% of sacsin staining showed co-localization with
MitoTracker ﬂuorescence. Signiﬁcantly, 40%+2% of Mito-
Tracker staining did not overlap with sacsin immunoreactivity
(similar values were obtained for the overlap between sacsin
and Hsp60 immunoreactivity). Analyses of the sacsin protein
sequence did not reveal the presence of a mitochondrial
leader sequence. Together, these observations suggest that a
proportion of sacsin localizes at or near the cytoplasmic face
of the mitochondria.
The N-terminus of sacsin contains
an ubiquitin-like domain
Bioinformatic analyses of the predicted amino acid sequence of
the full-length nineexon-encodedsacsin protein revealed apre-
viously unreported, putative UbL domain at the N-terminus
(Fig. 3A). UbL domains are present in ubiquitin-like proteins
(such as NEDD8 and SUMO-1) and in a variety of other multi-
domain proteins of diverse biological function (11). Many of
these proteins have been shown to bind components of the pro-
teasome via their UbL domain (11). These include the DNA
repair protein Rad23 (12), which has an N-terminal UbL
domain with 43% identity over 65 residues to the putative
sacsin UbL. Within the UbL domain, a potential consensus
sequence for proteasome interaction has been identiﬁed (13).
The sacsin UbL domain contains part of this motif (Fig. 3A).
Therefore, we tested the interaction between the sacsin UbL
domain and the proteasome. The N-terminus of sacsin (residues
1–124), including the putative UbL domain, was expressed in
CHO-1 cells as a chimeric protein with a FLAG epitope tag at
its C-terminus. The sacsin-UbL-FLAG was immunoprecipi-
tated and western blot analysis performed (Fig. 3B). The
proteasome-associated chaperone HSJ1, which functions as a
neuronal shuttling factor for the sorting of chaperone clients
Figure 2. Sacsin has a predominantly cytoplasmic localization with partial
mitochondrial overlap. Immunoﬂuorescent detection of sacsin in SH-SY5Y
cells using r-sacsin
1–17 (A, B) and r-sacsin
4489–4503 (C, D). The antibodies
were competed with immunizing peptide in (B and D). (E–G) Sacsin distri-
bution (red) partially overlapped with a ﬂuorescent mitochondria marker
(green). Cells were imaged by laser scanning confocal microscopy. Micro-
scope settings were constant for acquisition in the peptide competition exper-
iments. Scale bar ¼ 10 mm.
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Importantly, the 20S proteasomal alpha subunit C8 was
co-immunoprecipitated with the sacsin UbL domain.
To conﬁrm that this interaction was dependent on the UbL
domain, we mutated conserved UbL protein residues to
alanine. The sacsin-UbL domain double mutants L58/D60A
and R50A/L51A showed reduced co-immunoprecipitation
withC8(Fig.3B).Itwaspossiblethattheproteasomeinteraction
mayhavebeenbecauseoftheN-terminusofsacsinbeingubiqui-
tylated and targetedfordegradation.Tocontrol forthis wecom-
pared levels of the sacsin-UbL-FLAG in CHO-1 cells where the
proteasome had been inhibited by MG132 and untreated cells
(Fig. 3C). There was no increase in levels of the chimeric
protein after 16 h of MG132 treatment. However, we did
observe an increase in levels of ubiquitylated protein species
conﬁrming efﬁcient proteasome inhibition. Together, these
data indicate that sacsin has a functional N-terminal UbL
domain capable of interaction with the proteasome.
The sacsin J-domain is functional
Sacsin was suggested to be a type III Hsp40 family protein
based upon the presence of a putative J-domain near the
C-terminus of its predicted amino acid sequence. Alignment
of the human sacsin sequence with that of Hsp40/HDJ1
revealed approximately 60% identity over 30 residues
(Fig. 4A) exhibiting more divergence than most mammalian
J-domains. The structure of several J-domains has revealed
the presence of four a-helices and a loop region between
helices II and III (9), which contains the highly conserved
histidine-proline-aspartic acid (HPD) motif. To further
Figure 3. The N-terminus of sacsin contains a ubiquitin-like (UbL) domain
and interacts with the proteasome. (A) Alignment of sacsin’s putative UbL
domain with human UbL domain proteins and ubiquitin (Ubiqui). Residues
conserved between sacsin and the UbL proteins and/or ubiquitin are shown
in bold. Sacsin residues that match key hydrophobic amino acids which
may play a role in proteasomal targeting are indicated by asterisks. (B) The
proteasomal subunit C-8 co-precipitated with the N-terminus of sacsin, con-
taining the UbL domain. Lysates from CHO-1 cells transfected with wild-type
sacsin
1–124-FLAG, or sacsin
1–124-FLAG containing double mutations pre-
dicted to inhibit proteasome interaction, L58A/D60A and R50A/L51A, were
precipitated with anti-FLAG M2-conjugated agarose beads. HSJ1a-FLAG
was used as a positive control for proteasome co-precipitation. Western blot
analysis for FLAG-tagged proteins and the C8 subunit were performed. Aster-
isk highlights immunoglobulin chains. (C) To control for the possibility that
the sacsin
1–124-FLAG may interact with the proteasome through being tar-
geted for degradation, we investigated the effect of MG132 inhibition on cel-
lular levels of the chimeric protein. Western blot analysis was used to compare
cellular levels of sacsin
1–124-FLAG in cells treated with MG132 and control
cells. Proteasome inhibition was conﬁrmed by blotting cell lysates for ubiqui-
tylated proteins. Protein loading was monitored by blotting for actin.
Figure 4. The sacsin J-domain is functional. (A) Structure-aided alignment of
the sacsin J-domain to four other J-domains of known structure and the HSJ1
J-domain. Comparison with a consensus of highly conserved residues derived
from over 200 J-domain sequences is also shown. The J domains in the align-
ment are derived from Homo sapiens Sacsin, H. sapiens HSJ1, Escherichia
coli DnaJ, H. sapiens HDJ1, the murine polyoma virus T antigen (TAg) and
E. coli Hsc20. Those residues conserved in greater than 70% of all known J
domains are indicated below the alignment as a consensus (Con). The position
of each sequence is indicated at the start of each sequence. (B) Secondary
structure of the sacsin J-domain (PDB code 1IUR) compared with the
E. coli J-domain (PDB code 1XBL). The ribbon representations of the struc-
tures were rendered using PyMol. (C) The J-domain of sacsin was found to be
functional using an in vivo complementation assay. Agt DnaJ (Agt) and Agt
DnaJ with its J-domain swapped for that of sacsin (Sacsin) were able to
replace the lack of chromosomally expressed DnaJ and CbpA in E. coli
OD259 allowing growth at 378C. Agt J-domain (H33Q) (Agt(H33Q)) and
the Agt DnaJ-sacsin J-domain chimera with the H33Q substitution (Sac-
sin(H33Q)) were unable to replace DnaJ and CbpA in E. coli OD259, resulting
in a lack of growth at 378C. (D) Expression of Agt DnaJ and its chimeric
derivatives was conﬁrmed by western blot analysis.
1560 Human Molecular Genetics, 2009, Vol. 18, No. 9investigate if the sacsin J-domain was likely to be functional,
we compared its structure (PDB:1IUR) to the structure of the
Escherichia coli DnaJ J-domain (PDB: 1XBL) (15) (Fig. 4B).
Helix II of the Sacsin J-domain is similar in size and structure
to that of the J-domain of E. coli DnaJ with the histidine
residue of the sacsin HPD motif projecting into the J-domain
core in a comparable orientation (Fig. 4B). To test if the
sacsin J-domain was able to function in the Hsp70 chaperone
system, we utilized a bacterial in vivo complementation assay.
E. coli strain OD259 contains disrupted genes for DnaJ and
CbpA such that it will not grow at temperatures of 378C and
above (16) (Fig. 4C). Complementation with Agrobacterium
tumefaciens (Agt) DnaJ and chimeric proteins containing
J-domains from a wide range of organisms have been shown
to compensate for the lack of chromosomal-encoded E. coli
DnaJ and CbpA allowing growth at  378C (17,18). To
analyse the effect of sacsin’s J-domain in this experimental
system, the J-domain of Agt DnaJ was substituted with the
J-domain of human sacsin to make a chimeric protein. The
Agt DnaJ-sacsin was able to confer growth at  378C
(Fig. 4C). To conﬁrm that the complementation was dependent
on a DnaK (E. coli Hsp70)/sacsin J-domain interaction, the
histidine residue in the HPD motif was mutated to glutamine.
The modiﬁed Agt DnaJ-sacsin chimeric protein was unable to
reverse the thermosensitivity of E. coli OD259 (Fig. 4C), con-
sistent with previous studies that have also shown that the his-
tidine to glutamine substitution in the HPD motif disrupted the
ability of J-domains to functionally interact with Hsp70 (17).
Western blot analysis conﬁrmed that the chimeric proteins
were produced at similar levels (Fig. 4D).
Recently an ARSACS-causing compound heterozygous
mutation, Lys1715X/Arg4331Gln, was reported (7). The argi-
nine at position 4331 lies within helix II of the sacsin J-domain
and is partially conserved. However, a glutamine is occasion-
ally found at this position (equivalent to residue 27 in E. coli
DnaJ) in J-domains, for example in the murine polyoma virus
T antigen. Interestingly, we have previously shown that in
other J-domains substitution of an adjacent helix II arginine
residue (Arg26) for an alanine disrupted function (18). There-
fore, to investigate if the Arg4331Gln mutation affected the
function of the sacsin J-domain, we introduced it into Agt
DnaJ-sacsin chimeric protein and tested the effect of this
change in the bacterial complementation assay (Supplemen-
tary Material, Fig. S4). The Arg4331Gln change did not
affect bacterial growth at 378C (or more stringent temperatures
up to 448C) indicating that this change does not signiﬁcantly
impair sacsin J-domain function.
Sacsin is recruited to mutant ataxin-1 inclusions and
modulates the incidence of nuclei with large inclusions
Sacsin has previously been reported to be part of an ataxia
protein interactome (2). Moreover, mutant proteins linked to
many ataxic diseases form intracellular inclusions of ubiquity-
lated protein that contain interacting proteins, as well as mol-
ecular chaperones and components of the UPS. We therefore
tested if sacsin was recruited to nuclear ataxin-1 inclusions.
Constructs for expression of wild-type and pathogenic
ataxin-1, with polyglutamine tracts of 30 and 82 glutamine
residues, respectively, were transfected into SH-SY5Y cells,
and the cells subsequently stained for endogenous sacsin
(Fig. 5A). GFP-ataxin-1 has previously been reported to loca-
lize to the nucleus where the GFP-ataxin-1 nuclear staining is
either diffuse or in multiple small punctate foci, with an
increased incidence of large nuclear inclusions in cells expres-
sing polyglutamine-expanded ataxin-1 (19). Importantly, we
observed that sacsin was localized to intranuclear ataxin-1
inclusions in cells expressing GFP-ataxin-1[82Q].
Hsp70 proteins and their co-chaperones have been shown to
modulate aggregation in models of neurodegenerative dis-
eases. Polyglutamine-expanded ataxin-1 has been suggested
to favour a toxic and aggregation-prone conformation of the
protein that the wild-type protein backbone already has a ten-
dency to adopt (20). Furthermore, ataxin-1 has been shown to
interact with Hsp70 and its co-chaperones (20,21). As sacsin
was also recruited to GFP-ataxin-1[82Q] inclusions, we inves-
tigated the effects of siRNA-mediated sacsin knockdown on
ataxin-1 inclusion formation in SH-SY5Y cells. Western blot
analysis conﬁrmed effective knockdown of sacsin and
suggested a slight increase in GFP-ataxin-1[82Q] levels in
cells where sacsin was knocked-down. However, densito-
metric analyses revealed no signiﬁcant differences in the
level of GFP-ataxin-1 in cell lysates expressing wild-type
[Q30] and mutant [Q82] protein or between cells treated
with scrambled control and SACS siRNAs (Fig. 5B). We quan-
tiﬁed the percentage of cells expressing GFP-ataxin-1, when
co-transfected with control or SACS siRNA after 48 h
(Fig. 5C). We did not observe any difference in the number
of cells expressing GFP-ataxin-1[30Q] upon sacsin knock-
down. Therefore, SACS siRNA is not inherently toxic to
SH-SY5Y cells. The expression of GFP-ataxin-1[82Q] leads
to cell death (22,23). Importantly, there was a signiﬁcant
(P , 0.05) reduction in the number of cells expressing
GFP-ataxin-1[82Q] upon sacsin knockdown after 48 h. To
control for the possibility that the observed reduction was
because of less GFP-ataxin-1[82Q] expression as opposed to
cell death, we repeated the experiment using DsRedII to
monitor transfected cell survival. In cells co-transfected with
DsRedII and GFP-ataxin-1[82Q], the number of
DsRedII-expressing cells was reduced to a similar extent
when treated with SACS siRNA (not shown), conﬁrming that
there was enhanced toxicity of the GFP-ataxin-1[82Q] when
sacsin was knocked down.
We next examined the phenotype of cells expressing
GFP-ataxin-1 more closely. In SH-SY5Y cells transfected
with scrambled control siRNA and GFP-ataxin-1[30Q], we
observed a diffuse nuclear ataxin-1 staining in 23+2% of
cells. In 57+2% of nuclei, the diffuse staining was
accompanied by multiple small punctate inclusions of
,1.5 mm in diameter. In 20+1% of cells fewer, large
( 1.5 mm), ataxin-1 inclusions were observed in the nucleus
(Fig. 5D). When pathogenic GFP-ataxin-1[82Q] was
expressed, the percentage of cell nuclei harbouring large
inclusions increased dramatically (55+3% had large
inclusions). SACS siRNA on GFP-ataxin-1[30Q] did not sig-
niﬁcantly alter the incidence of small punctate or large
inclusions, compared with control siRNA. However, in cells
expressing GFP-ataxin-1[82Q] downregulation of sacsin
resulted in a signiﬁcant (P , 0.0001) reduction in the percen-
tage of cells with large nuclear inclusions, compared with cells
Human Molecular Genetics, 2009, Vol. 18, No. 9 1561treated with the control siRNA, and a commensurate increase
in the percentage of cells with the diffuse and punctate nuclear
phenotypes (Fig. 5C). The reduction in cells with large nuclear
inclusions correlated with the overall reduction in cell number
(approximately 35%), suggesting that this population of cells
was the most affected by SACS siRNA. The frequency of
nuclei with inclusions was not signiﬁcantly different in cells
transfected with control siRNA and cells where siRNA was
omitted from the transfections (not shown).
DISCUSSION
The ARSACS gene product, sacsin, was originally reported to
be encoded by a single large exon. However, data presented in
Figure 5. Sacsin knockdown reduces the incidence of cells with large nuclear inclusions of polyglutamine-expanded ataxin-1. (A) Confocal immunoﬂuorescence
microscopy showing recruitment of sacsin to ataxin-1 nuclear inclusions and in particular large inclusions of GFP-ataxin-1[82Q]. The scale bar represents 10 mm.
(B) Western blot analysis conﬁrming sacsin knockdown. Total cellular levels of ataxin-1 were not signiﬁcantly affected by sacsin knockdown. (C) The total
number of cells expressing GFP-ataxin-1 was compared in cells co-transfected with SACS siRNA, or a scrambled control siRNA. Sacsin knockdown did not
affect the number of cells expressing GFP-ataxin-1[30Q], but did cause a reduction in the number of cells expressing GFP-ataxin-1[82Q] after 48 h. The fre-
quency of ataxin-1-expressing cells with SACS siRNA is shown as a percentage of the remaining ataxin-1-expressing cells in the control siRNA treatment. (D)
The distribution of ataxin-1 in the nuclei of SH-SY5Y cells co-transfected with GFP-ataxin-1[30Q] or GFP-ataxin-1[82Q] and SACS siRNAs, or a scrambled
control siRNA, was quantiﬁed. Confocal images of nuclei with representative ataxin-1 distributions are shown. Ataxin-1 was either diffusely localized within the
nucleus, localized to multiple small punctate foci, or present in fewer larger inclusions. Sacsin knockdown reduced the number of cells with large inclusions in
cells expressing GFP-ataxin-1[82Q]. A minimum of 50 transfected cells were scored for each treatment from ﬁve separate transfections. Scoring was conducted
blind to experimental status 48 h post-transfection. P , 0.05 are indicated with an asterisk.
1562 Human Molecular Genetics, 2009, Vol. 18, No. 9this study are consistent with a SACS mRNA, derived from a
nine-exon gene, expressing a 4579 amino acid sacsin isoform,
with a molecular weight of 520 kDa. This is in agreement with
the recent identiﬁcation of ARSACS mutations in exons 6, 7
and 8 of SACS (7,8).
Our data indicate that sacsin is widely expressed in the brain.
SACS message and sacsin protein were expressed at high levels
in Purkinje cells. Consistent with this, cerebellar Purkinje cell
degeneration is a common pathology of ataxias, including
ARSACS.Precerebellarnucleiwhichprojectafferentprocesses
to the cerebellum also had signiﬁcant expression of sacsin
suggesting that input to the cerebellum could also be affected
by altered sacsin function. Corticospinal tract and peripheral
nerveaxonal degenerationand changes inmyelinationand con-
ductance are reported in ARSACS patients (5). Interestingly,
neuronscontributingtothecorticospinal tractandcranial moto-
neurones express high levels of sacsin and axons contain sacsin
immunoreactivity.
Very large proteins, such as sacsin, are extremely difﬁcult to
express heterologously. Therefore, to elucidate the cellular
role of sacsin we have adopted a strategy of analysing the
function of speciﬁc domains and siRNA. Bioinformatic analy-
sis revealed that the N-terminus of human sacsin contains a
putative UbL domain. This domain co-immunoprecipitated
with the 20S proteasomal subunit and thus can occur in a
complex with the proteasome, possibly interacting with it
directly. Interestingly, a number of proteins that function in
the UPS are linked to ataxias. These include ataxin-3, which
contains a ubiqutin interaction motif (UIM) and functions as
a de-ubiquitinating enzyme (24). Furthermore, a number of
protein–protein interactions have been observed between
UbL and UIM domain proteins. For example, the UbL
domain protein PLIC-1, which is a component of the quality
control machinery that regulates protein aggregation, is able
to interact with both the proteasome and some UIM domain
proteins, including ataxin-3 and HSJ1 (25). Thus, it is possible
that sacsin may also interact with UIM-containing proteins.
The human proteome contains 12 Hsp70 family members,
the activity of which is regulated by numerous co-chaperones,
including nearly 50 Hsp40 family members (26). Hsp70
switches from a low substrate afﬁnity when bound to ATP,
to a high afﬁnity state upon the hydrolysis of ATP to ADP
(27). This cycle is regulated by Hsp70 co-chaperones and in
particular Hsp40 proteins, which interact with Hsp70 via the
J-domain, stimulating ATP hydrolysis and altering substrate-
binding (27). Importantly, Hsp40 proteins act to recruit the
Hsp70 machinery to speciﬁc cellular locales and functions.
We demonstrated that the sacsin J-domain is able to function
with the E. coli Hsp70, DnaK, thus conﬁrming that sacsin is a
type III Hsp40 protein and supporting an alternative Hsp40
family member designation of DNAJC29 (26). As a com-
ponent of the sacsin staining was observed to be associated
with mitochondrial markers, sacsin could potentially recruit
a Hsp70 to speciﬁc function at the surface of mitochondria.
It will be important to establish with which Hsp70 partners
sacsin functions in vivo to further understand its cellular
role. Particularly, as although the Arg4331Gln change,
which was reported as a compound heterozygous sacsin
mutation, did not affect the ability of the sacsin J-domain to
function with the E. coli Hsp70, DnaK, it may inhibit the
ability of the sacsin J-domain to stimulate the ATPase
activity of other Hsp70 proteins. Interestingly, in addition
to its J-domain, sacsin also contains multiple regions of
homology to Hsp90 (6), further suggesting a possible chaper-
one function.
We observed a signiﬁcant enhancement in the toxicity of
GFP-ataxin-1[82Q] when sacsin levels were reduced by
siRNA. This reduction in cell number correlated with the
loss of cells with the large nuclear inclusion phenotype from
the population. These data suggest that sacsin is protective
against polyglutamine-expanded ataxin-1 toxicity. Interest-
ingly, the overall level of GFP-ataxin-1[82Q], detected by
western blot analysis of cell lysates, was not signiﬁcantly
altered after sacsin knockdown, even though there was a
reduction in the number of cells with detectable GFP signal.
This implies that the remaining cells have higher levels of
GFP-ataxin-1[82Q] and may indicate a role for sacsin in the
degradation of aberrantly folded ataxin-1.
The dynamics of ataxin-1 inclusion formation is controver-
sial. Ataxin-1 nuclear inclusion formation has been shown to
be dependent on RNA-binding. Wild-type ataxin-1, has been
reported to shuttle between the nucleus and cytoplasm,
whereas the polyglutamine-expanded mutant protein cannot
shuttle (28). This suggests a gain of function of the mutant
protein such as retention of associated RNAs or proteins
within the nucleus. Conversely, it has also been reported that
polyglutamine expansion does not affect nuclear shuttling,
but enhances the intracellular kinetics of ataxin-1 (29). Inhi-
bition of the proteasome leads to the apparent fusion of
ataxin-1 nuclear inclusions and an increase in their size (28),
while the type I Hsp40 protein HDJ-2/DnaJA1 has been
reported to suppress ataxin-1 aggregation and is localized to
inclusions (30). It is unknown if sacsin’s localization to
ataxin-1-[Q82] inclusions, and effect on their incidence, is
dependent on its J-domain, or UBL domain, or if it requires
sacsin to bind ataxin-1 as a chaperone.
A recent study undertook a yeast two-hybrid-based screen
to develop a protein–protein interaction network for proteins
involved in inherited ataxias and disorders of Purkinje cell
degeneration (2). The C-terminal region of sacsin was found
to share four interacting partners with other ataxia proteins
(2). The best studied of these is PICK1 (protein interacting
with C-kinase), which was identiﬁed as binding ataxin-7,
PRKCG, aprataxin and frataxin. Interestingly, frataxin,
mutations in which cause the autosomal recessive disease
Friedreich’s ataxia, is also targeted to mitochondria. The
recruitment of sacsin to polyglutamine-expanded ataxin-1
intranuclear inclusions and the disappearance of cells with
these inclusions, when sacsin levels are reduced by siRNA,
further points to sacsin being in common cellular pathways
with other ataxia proteins.
Type I and II Hsp40 proteins predominantly act to stimulate
Hsp70 general protein folding function, while type III Hsp40
proteins recruit Hsp70s to specialized roles. Sacsin’s large
size and multiple domains suggest that it may have additional
cellular roles to protecting against mutant ataxin-1 expression.
We hypothesize that sacsin may act as a molecular scaffold for
assembly of a speciﬁc protein complex and that regulation of
this complex requires integration of molecular chaperone
machinery and the UPS.
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Sacsin antibody generation and characterization
Two rabbit antisera were raised against the human sacsin pep-
tides DYAVRGKSDKDVKPT (amino acid residues 4489–
4503) and METKENRWVPVTVLPGC (amino acid residues
1–17) conjugated to KLH. The antisera were afﬁnity-puriﬁed
against immunizing peptides. For western blotting of sacsin,
in tissue and SH-SY5Y cells, samples were separated on a
4–12% NuPAGE gel (Invitrogen).
Analysis of sacsin localization
Adult male Wistar rats were used for in situ and immunohis-
tochemical analyses of SACS mRNA and sacsin protein distri-
bution in the brain. In situ hybridization was performed using
radioactive oligonucleotide probes and emulsion autoradiog-
raphy as described previously (31). Oligonucleotide probes
complementary to rat SACS mRNA (accession number
XM_001063390) at nucleotides 569–602 (aagccggtctcagcgaa
gatgcgctccttgaggt), 13881–13914 (aaggtagcacttgaagcacacc
cactcattggca) and 14062–14095 (acctttgagagtatgtctgtccagca
gagggagg) were tested and found to give an identical cellular
distribution for sacsin. Free-ﬂoating sections of 40 mm were
processed for immunohistochemistry with standard method-
ologies previously described (32). Immunoﬂuorescent proces-
sing and subsequent confocal microscopy were as described
previously (14). The overlap between sacsin staining and
mitochondrial markers was quantiﬁed from 10 representative
images using the co-localization function of the MetaMorph
7.5 image analysis software (Molecular Devices).
Co-immunoprecipitation of the N-terminus
of sacsin with the proteasome
The 50 end of the SACS open reading frame was sub-cloned
into p3xFLAG-CMV-14, such that the N-terminal 124 amino
acids of sacsin, encompassing the UbL domain, was expressed
with a FLAG-tag fused at the C-terminus. UbL domain
mutations L58/D60A and R50A/L51A were introduced to
this construct by site-directed mutagenesis. CHO-1 cells tran-
siently transfected with constructs expressing sacsin
1–124-
FLAG or HSJ1-FLAG, which was used as a positive control
(14), were harvested in 50 mM Tris HCl pH 7.4, 150 mM
NaCl, 1 mM EDTA, 0.5% Triton X-100, protease inhibitors.
Supernatant from a 17 000g 30 min centrifugation were incu-
bated at 48C with anti-FLAG (M2)-conjugated agarose beads
(Sigma). After 16 h, beads were washed and proteins eluted
in sodium dodecyl sulphate–polyacrylamide gel electrophor-
esis sample buffer and subjected to western blot analyses.
Co-immunoprecipitated proteasome subunit was detected
with anti-human C8 (Afﬁniti). For proteasome inhibition,
cells were incubated in media containing 10 nM MG132
for 16 h.
Bacterial complementation assay for J-domain function
Complementation assays were performed in E. coli strain
OD259 (16) as described previously (17). Brieﬂy, the pQE30-
derived pRJ30 vector containing the A. tumefaciens DnaJ
coding sequence served as a base vector for J-domain
swapping using the strategy we have outlined before (18).
The coding region for the sacsin J-domain (residues 4296–
4384) was ampliﬁed by PCR from BAC clone RP11-40O20
(http://bacpac.chori.org). The histidine to glutamine mutations
of the sacsin HPD motif was produced by site-directed muta-
genesis. E. coli OD259 cells exogenously producing Agt DnaJ
and Agt DnaJ(H33Q) served as controls. Western blot analysis
using an anti-His antibody was performed on whole cell
lysates of E. coli OD259 and its transformants producing
6xHis-tagged Agt DnaJ and chimeric proteins to conﬁrm
equivalent levels of expression.
SACS siRNA-mediated knockdown in
ataxin-1-expressing cells
Target sequences in exons 6 (GGATGATCCTCGAAGGTC),
7 (GCGGCCGAATTCTATAAAG) and 9 (CGTAAGATTTC
TAGATGAC) of SACS were identiﬁed and used to generate
siRNA molecules (Ambion). siRNAs were validated individu-
ally by comparison of levels of SACS mRNA in SH-SY5Y-
transfected cells with the siRNA or a scrambled control by
RT-PCR (Supplementary Material, Fig. S5). A mixture of
the three siRNAs, at a concentration of 20 mM was used in sub-
sequent experiments. siRNAs were co-transfected with
ataxin-1 constructs and cells processed for immunoﬂuores-
cence or western blot analysis after 48 h. DR-RedII (Clontech)
was used at a ratio of 1:3, to GFP-ataxin-1, to monitor trans-
fection efﬁciency. Quantiﬁcation of transfected cells and
scoring of cell nuclei containing ataxin-1 inclusions was per-
formed blinded to experimental status. A Mann–Whitney U
test was used for statistical analysis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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